内容紹介
A Case of a Patient with Gastric Cancer and Peritoneal Dissemination Who Survived for More than 10 Years after Successful Treatment with S-1
Summary
A 50-year-old female patient underwent distal gastrectomy and intraperitoneal CDDP administration for advanced gastric cancer accompanied by severe peritoneal dissemination. She valued her quality of life and chose an oral anticancer drug, S-1, as a postoperative chemotherapy agent. S-1 was administered at a dose of 100 mg/body/day for 4 weeks, followed by a 2-week rest. There were no adverse events due to S-1 and no exacerbation of peritoneal dissemination in the 5 years following surgery. The S-1 administration schedule was then changed to alternate-day administration. Eight years after the surgery, the patient discontinued S-1 treatment and has since survived for 11 years with no obvious cancer recurrence.
要旨
症例は50歳,女性。胃癌の診断にて手術を施行し,広範囲に多数の腹膜播種を認めたため,減量手術とcisplatin(CDDP)の腹腔内投与を行った。術後化学療法を施行するに当たり,患者はQOLを重視したため,術後第13病日からS-1の単独投与(4週連日投与,2週休薬)を開始した。その後,外来にて経過をみていたが再燃徴候は認められず,5年後にS-1隔日投与に変更した。術後8年目の精査でも再発所見なく,以後はS-1内服を終了し,11年経過した現在も無再発生存中である。
目次
Summary
A 50-year-old female patient underwent distal gastrectomy and intraperitoneal CDDP administration for advanced gastric cancer accompanied by severe peritoneal dissemination. She valued her quality of life and chose an oral anticancer drug, S-1, as a postoperative chemotherapy agent. S-1 was administered at a dose of 100 mg/body/day for 4 weeks, followed by a 2-week rest. There were no adverse events due to S-1 and no exacerbation of peritoneal dissemination in the 5 years following surgery. The S-1 administration schedule was then changed to alternate-day administration. Eight years after the surgery, the patient discontinued S-1 treatment and has since survived for 11 years with no obvious cancer recurrence.
要旨
症例は50歳,女性。胃癌の診断にて手術を施行し,広範囲に多数の腹膜播種を認めたため,減量手術とcisplatin(CDDP)の腹腔内投与を行った。術後化学療法を施行するに当たり,患者はQOLを重視したため,術後第13病日からS-1の単独投与(4週連日投与,2週休薬)を開始した。その後,外来にて経過をみていたが再燃徴候は認められず,5年後にS-1隔日投与に変更した。術後8年目の精査でも再発所見なく,以後はS-1内服を終了し,11年経過した現在も無再発生存中である。